Journal
JACC-HEART FAILURE
Volume 10, Issue 2, Pages 119-128Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.jchf.2021.09.007
Keywords
ARNI; biomarker; BNP; HFrEF; sacubitril; valsartan
Categories
Funding
- Novartis AG
- South-Eastern Norway Regional Health Authority
- Hutter Family Professorship
- Abbott
- Alnylam
- AstraZeneca
- Bayer
- Novartis
- Amgen
- Bellerophon
- Celladon
- Gilead
- GlaxoSmithKline
- Ionis Pharmaceutics
- Lone Star Heart
- Mesoblast
- MyoKardia
- National Institutes of Health/National Heart, Lung, and Blood Institute
- Sanofi Pasteur
- Theracos
- Applied Therapeutics
- Innolife
- Novartis Pharmaceuticals
- Abbott Diagnostics
- Brigham and Women's Hospital
Ask authors/readers for more resources
This study assessed changes in B-type natriuretic peptide (BNP) among patients with heart failure with reduced ejection fraction (HFrEF) treated with sacubitril/valsartan (Sac/Val) according to standard prescribing information. The results showed that there was no significant overall increase in BNP concentrations in patients with HFrEF treated with Sac/Val, and patients demonstrated an increase in urinary cyclic guanosine monophosphate (ucGMP) regardless of the trajectory of BNP change.
OBJECTIVES This study assessed changes in B-type natriuretic peptide (BNP) among patients with heart failure with reduced ejection fraction (HFrEF) treated with sacubitril/valsartan (Sac/Val) according to standard prescribing information. BACKGROUND Through inhibition of neprilysin, Sac/Val may increase BNP concentrations. METHODS In an individual patient analysis from the EVALUATE-HF (Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction) (n = 221) and the PROVE-HF (Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes) (n = 146) studies, we examined changes in BNP, N-terminal pro-BNP (NT-proBNP), and urinary cyclic guanosine monophosphate (ucGMP) from baseline to week 4 and week 12. RESULTS Median (IQRs) concentration of BNP at baseline, week 4, and week 12 were 145 [IQR: 55-329], 136 [IQR: 50338], and 135 [IQR: 51-299] ng/L, respectively. There was no significant change from baseline to week 4 (0% [-30% to +41%]; P = 0.36) or week 12 (+1% [-36% to +50%]; P = 0.97). By week 12, one-half of the study participants had a BNP decline. There was no association between Sac/Val dose and BNP changes. Change in BNP was directly associated with change in NT-proBNP (rho: = 0.81; P < 0.001), which decreased by-30% (-50% to-8%) and-32% (-54% to-1%) to weeks 4 and 12 (P < 0.001 for both). In contrast, change in BNP was only weakly associated with change in ucGMP (rho: = 0.19; P < 0.001). Increases in ucGMP were observed regardless of whether BNP was decreased (+11% [-34% to +115%]), unchanged (+34% [-15% to +205%]), or increased (+57% [-12% to +14%]). CONCLUSIONS In this pooled analysis of patients with HFrEF with standard indications for Sac/Val treatment, there was no significant overall increase in BNP concentrations, and patients demonstrated increase in ucGMP regardless of the trajectory of BNP change. (Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction [EVALUATE-HF]; NCT02874794) (Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes [PROVE-HF]; NCT02887183). (J Am Coll Cardiol HF 2022;10:119-128) (c) 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available